



1 July 2026

**ASX ANNOUNCEMENT**

**Control Bionics to present at Life Science Intelligence Asia**

Control Bionics Limited (ASX: CBL) advises Chief Executive Officer and Managing Director, Jeremy Steele, will present at the Life Science Intelligence (LSI) Asia 2026 Emerging Medtech Summit, being held in Singapore, from 30 June to 2 July 2026.

Mr Steele will deliver a company presentation and participate in the panel session, "Designing Medtech for the Consumer World", alongside other representatives from the medtech, clinical and life sciences sectors.

A copy of the presentation to be delivered at LSI Asia 2026 is being released to the ASX today.

LSI Asia is an international medtech forum that brings together emerging medical technology companies, investors, strategics and clinicians. The full program can be seen here <https://www.lsiassummit.com/>.

Control Bionics' participation reflects interest in the Company's non-invasive, surface electromyography-based neural-signal platform, which captures the body's physiological signals, including the electrical activity generated by muscles, and converts them into measurable data.

This announcement has been authorised for release to the ASX by the Board of Control Bionics Limited.

For further information, please contact:

Jeremy Steele  
CEO and Managing Director  
[jsteele@controlbionics.com](mailto:jsteele@controlbionics.com)

Brett Crowley  
Company Secretary  
[brettcrowley@controlbionics.com](mailto:brettcrowley@controlbionics.com)

## **About Control Bionics**

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.